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Abstract
Background: Data on which to base definitive recommendations on the doses and duration of therapy for genotype 3 HCV/
HIV-coinfected patients are scarce. We evaluated the efficacy of a lower peginterferon-a 2a dose and a shorter duration of
therapy than the current standard of care in genotype 3 HCV/HIV-coinfected patients.
Methods and Findings: Pilot, open-label, single arm clinical trial which involved 58 Caucasian HCV/HIV-coinfected patients
who received weekly 135 mg peginterferon-a 2a plus ribavirin 400 mg twice daily during 20 weeks after attaining
undetectable viremia. The relationships between baseline patient-related variables, including IL28B genotype, plasma HCV-
RNA, ribavirin dose/kg, peginterferon-a 2a and ribavirin levels with virological responses were analyzed. Only 4 patients
showed lack of response and 5 patients dropped out due to adverse events related to the study medication. Overall,
sustained virologic response (SVR) rates were 58.3% by intention-to-treat and 71.4% by per protocol analysis, respectively.
Among patients with rapid virologic response (RVR), SVR and relapses rates were 92.6% and 7.4%, respectively. No
relationships were observed between viral responses and ribavirin dose/kg, peginterferon-a 2a concentrations, ribavirin
levels or rs129679860 genotype.
Conclusions: Weekly 135 mg pegIFN-a 2a could be as effective as the standard 180 mg dose, with a very low incidence of
severe adverse events. A 24-week treatment duration appears to be appropriate in patients achieving RVR, but extending
treatment up to just 20 weeks beyond negativization of viremia is associated with a high relapse rate in those patients not
achieving RVR. There was no influence of IL28B genotype on the virological responses.
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Introduction
Although data on which to base definitive recommendations on
the dosing and duration of therapy for co-infected patients are
limited, the current standard therapy for chronic hepatitis C
(CHC) genotype 3 (G3) is the combination of weekly 180 mg
pegylated interferon-a (pegIFN-a) 2a or 1.5 mg/kg pegIFN-a 2b
and 800 mg daily ribavirin (Rbv) for 48 weeks [1,2]. This
recommendation is based on a few randomized trials with both
pegIFN-a 2a [3] and pegIFN-a 2b [4–7] and several cohort
studies [8–10] in which sustained virologic response (SVR) rates
between 34% and 82% were observed. In addition, as the HCV
protease inhibitors are less active against G3 [11], the combination
of pegIFN-a and Rbv will remain the key drugs for this genotype.
Besides, both pegIFN-a formulations are associated with large
interpatient variability in plasma concentrations after specific
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doses [12,13]. Previously, we evaluated the influence of pegIFN-a
2a plasma concentrations on the virologic response in HCV/HIV
coinfected patients and, in contrast to G1/4, we found no
association between pegIFN-a-2a levels and SVR in patients with
G3 [14]. This fact, along with the similar SVR rate achieved for
these G with lower doses of pegIFN-a 2a or 2b monotherapy [15–
17], suggest that the pegIFN-a-2a levels achieved with the 180 mg
weekly doses were in the plateau portion of the concentration–
response curve for patients with G3.
On the other hand, the current standard treatment is associated
with frequent and, sometimes, severe adverse events (AEs) and
requires an extended duration of therapy. Therefore, a goal must
be to find the minimal dose and duration that is effective for
achieving SVR, decreasing the incidence or severity of AEs and
enhancing adherence, particularly in HIV-coinfected patients in
whom the treatment of HCV infection has been associated with a
high rate of intolerance. In this study we evaluated the efficacy and
safety of a lower pegIFN-a 2a dose (135 mg) plus flat dose ribavirin
with shorter therapy duration (20 weeks after attaining undetect-
able serum HCV-RNA) in a cohort of HIV-coinfected patients
with CHC G3. In this study we evaluated the efficacy and safety of
a lower pegIFN-a 2a dose (135 mg) plus flat dose ribavirin with
shorter therapy duration (20 weeks after attaining undetectable
serum HCV-RNA) in a cohort of HIV-coinfected patients with
CHC G3. After the study had begun, it was known that single
nucleotide polymorphisms (SNPs) nearby the IL28B gene are
strong predictors of response to pegIFN-a-2a plus Rbv treatment
in CHC [18,19]. So, we additionally assessed the influence of
IL28B rs12979860 polymorphisms on the virological response to
this regimen.
Methods
Ethics Statement
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The study protocol was approved by the Agencia
Espan˜ola del Medicamento, and a central ethics committee
(Comite´ Autono´mico de Ensayos Clı´nicos, Consejerı´a de Salud,
Junta de Andalucı´a). The study was conducted according to the
Declaration of Helsinki and current guidelines on Good Clinical
Practices. All patients provided written informed consent. This
study is registered at NIH register (ClinicalTrials.gov:
NCT00553930) and EMEA (Nu EudraCT: 2007-000814-35).
Design and study population
This was a pilot, open-label, single arm, investigator-initiated
clinical trial in which Caucasian HCV treatment naive patients
were prospectively enrolled in four infectious disease units in Spain
from January 2008 to August 2009. The trial ended after the
completed follow-up of the last enrolled patient. Patients were
eligible if they were older than 18 years, HIV-coinfected, and had
CHC or compensated cirrhosis by HCV G3. Although the initial
protocol contemplated the inclusion of patients carrying HCV G2,
these were excluded from analysis as only two of these patients
were enrolled. Patients were treated under routine clinical care
conditions, and liver biopsy was not mandatory for inclusion in the
study. Patients were excluded if they had active HIV-related
opportunistic infection, cancer, hepatitis B coinfection, other
causes of liver disease, hemoglobinopathies, previous history of
severe psychiatric illness, autoimmune diseases, abnormal renal
function, or pregnancy. There were no exclusion criteria regarding
methadone use, CD4 cell counts, plasma HIV-RNA, or
concurrent antiretroviral therapy.
Laboratory tests
HCV genotypes were determined using a reverse hybridization
assay (Inno-Lipa HCV II; Bayer, Barcelona, Spain). Plasma HCV-
RNA loads were measured by a quantitative PCR assay (COBASH
AmpliPrep/COBASH TaqManH HCV Test; detection limit of
15 IU/ml) at baseline, after weeks 1, 2, 4, and monthly thereafter
until the end of treatment, and again at 6 months after completing
treatment. Hematological and biochemical profiles were also
assessed at the same time points. CD4 counts (standard flow
cytometry) and plasma HIV-RNA (Cobas AmpliPrep-Cobas
TaqMan HIV-1 test, v.2.0, Basel, Switzerland) were measured
at baseline and every three months thereafter. Hepatic fibrosis was
evaluated by pretreatment liver biopsy according to the Scheuer’s
scoring system [20], or by transient elastography (FibroscanH,
Echosens) for which values of $11 and $14 kPa were considered
as F3 and F4 fibrosis stages, respectively.
Genomic DNA was extracted from whole blood provided in
EDTA tubes using the QIAmp DNA Blood Kit (Qiagen). The
rs129679860 SNP was genotyped with a custom TaqMan
genotyping assay (Applied Biosystems) on DNA isolated from
whole blood samples. The DNA was genotyped according to the
manufacturer’s instructions on a MX3005 thermocycler using
MXpro software (Stratagene).
Plasma samples for PegIFN-a-2a and Rbv Cmin determinations
were drawn on the morning of the day scheduled for weekly
administration of pegIFN-a-2a after 11.45 to 12.15 hours to the
previous Rbv dose (otherwise, blood samples were discarded) at
weeks 1, 2, 4, and monthly afterwards until the end of therapy.
Samples were stored at 280uC until tested. Plasma pegIFN-a-2a
and Rbv concentrations were assayed by enzyme-linked immu-
nosorbent assay Hu-INF-a (PBL Biomedical Laboratories, Piscat-
away, NJ), and reverse-phase high-performance liquid chroma-
tography (HPLC-UV) as previously described [14]. All calibration
standards, quality control samples, and study samples were
analyzed in duplicate. Results are shown as the mean of the
duplicates for the study samples.
End-points and assessment of efficacy and safety
The primary efficacy end-point was SVR, defined as undetect-
able serum HCV-RNA at 24 weeks after completion of treatment.
Efficacy data were assessed by both intention-to-treat (ITT) and by
per-protocol analysis. Secondary end-points were to assess the
influence of IL28B polymorphisms on SVR and the relationship
between the plasma pegIFN-a-2a and Rbv concentrations and
virological responses in patients receiving treatment.
Rapid virologic response (RVR) was defined as a plasma HCV-
RNA,15 IU/mL at week 4 of treatment. Early virologic response
(EVR) was defined as a plasma HCV-RNA,15 IU/mL or a
decrease of $2 log10 IU/ml at week 12 of treatment or earlier,
respectively. End of treatment response (ETR) was defined as
undetectable serum HCV-RNA at the end of therapy. Relapses
were defined as a detectable serum HCV-RNA at any time point
after attaining ETR.
Safety was assessed by means of AEs reported by patients or
detected by investigators, and laboratory results at scheduled visits
on weeks 1, 2, 4, 8, 12, and monthly thereafter until the end of
therapy, and categorized via a standardized toxicity grade scale
(AIDS Clinical Trials Group). For toxicity and response
investigations, analysis dropouts were considered until the last
available visit.
Drug treatment
Patients started treatment with the combination of weekly
135 mg pegIFN-a-2a plus oral Rbv (400 mg twice daily), and a
IL28B and HCV Genoype 3 Treatment Response
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planned duration of 20 weeks after attaining undetectable serum
RNA-HCV. Treatment was discontinued at week 12 in patients
not achieving EVR, and these cases were considered as virological
failures. Antiretroviral treatment and use of erythropoietin
remained at the responsible physicians’ judgment.
Statistical analysis
This pilot study was designed as a single-arm, uncontrolled trial,
with a historical comparison. For ‘a priori’ sample size
calculations, the Apricot trial, the largest clinical trial with
pegIFN-a-2a plus Rbv conducted in HCV/HIV-coinfected
patients (3,21) so far, was considered as historical reference. The
SVR rate observed in patients harbouring HCV genotype 2 or 3 in
the Apricot trial was 62%. Assuming a 57% SVR rate in our
patients, a sample size of 60 patients would be required to reach a
80% statistical power with an asymptotic unilateral confidence
interval of 95% and a 10% noninferiority margin (Ene 3.0; e-
Biometria, Madrid, Spain).
Continuous variables are expressed as median (range) and
categorical variables are expressed as the number of cases
(percentage). For this analysis, the level of 800000 IU/mL was
chosen as the cut-off point for plasma HCV-RNA concentration.
Intraindividual variability in plasma concentrations was assessed
by measuring the coefficient of variation (CV = standard devia-
tion/mean6100) of all the available values from each patient
throughout the follow-up. Interindividual variability was calculat-
ed using the CV for the geometric mean of each subject. Ninety-
five percent confidence intervals (CI95) around single proportions
were calculated as p61.96
ﬃﬃﬃﬃﬃ
pq
p
n
where p is the proportion and
q = 1 2 p. The relationships between virological responses and
potentially predictive variables were examined using x2 tests. To
assess the independence of these factors, a logistic regression analysis
was used in which all variables with P values below 0.2 in the initial
analyses were included. All tests were two-tailed, and the differences
were considered significant when P was,0.05. Statistical calcula-
tions were performed with the Statistical Product and Service
Solutions for Windows (15.0 version, SPSS, Chicago, IL).
Results
Characteristics of the study population
A total of 60 Caucasian HCV/HIV-1-coinfected patients (G2,
2; G3, 58) were included in the study in four infectious disease
units in Spain from January 2008 to August 2009. The trial ended
after the completed follow-up of the last enrolled patient. The two
patients with HCV G2 were excluded from analysis for
homogenizing results. Baseline characteristics are summarized in
table 1. Information on liver fibrosis was available for 56 patients
(by liver biopsy in 23, by transient elastography in 41, and by both
techniques in 16); 21 (36.2%) of these 58 patients had cirrhosis.
Baseline HCV-RNA was similar in patients with CC rs129679860
IL28B genotype (5.93 log10 IU/ml; range, 3.02 – 7.15) and in
those carrying the T allele (5.55; range, 3.52 – 7.13; p = 0.4).
Treatment efficacy and safety
The study flow diagram and virological responses are shown in
figure 1, and table 2, respectively. Fifteen patients (25.8%)
prematurely discontinued treatment, 4 (6.8%) due to lack of
response and 11 due mainly to AEs. Although 55 patients (94.8%)
presented one or more AEs (table 3), especially within the first 12
weeks of therapy, the AEs considered related to the study
medication led to discontinuation of treatment in only 4 (6.9%)
patients (nausea and vomiting, 2; depression, 1; pneumococcal
pneumonia, 1). In 5 additional patients the AEs were considered
unrelated to the study medication. Ten of these latter patients
could be considered as responders as 4 of them discontinued
therapy with a plasma HCV-RNA reductions of 2.59 to 3.65 after
1 or 2 weeks of therapy and 6 of them 7 remaining patients did it
after reaching a negative viremia at week 8 or 12. Finally, 43
patients completed the treatment (figure 1) with a median duration
of 24 weeks (range, 24 – 42). Only 12 patients extended treatment
beyond 24 weeks (28, 6; 32, 2; 36, 3, and 42, 1), and 3 patients had
a treatment exposition less than 80% of the planned treatment.
There were no dose reductions of pegIFN-a-2a or Rbv, and only 2
patients required erythropoietin (30000 IU weekly) from weeks 4
and 20 onwards, respectively.
Overall, SVR rates were 56.9% (CI95: 43.8 – 70.0%) by ITT,
and 70.2% (CI95: 56.6 – 83.8%) by per protocol analysis, with a
relapse rate of 23.2% (CI95: 10.1 – 36.4%). Among those 28
patients who had RVR, 24 (85.7%) attained SVR by ITT analysis,
with rates of SVR and relapses of 92.3% and 7.7%, respectively,
by per-protocol analysis. On the other hand, among the 32
patients who did not achieve RVR, 9 of them (28.1%) attained
SVR and 8 relapsed.
Table 1. Baseline characteristics of the patients included in
the study.
Male, no. (%) 48 (82.8)
Age, years, M (range) 44 (27 – 57)
Weight, kg, M (range) 69 (41.3 – 102.0)
Risk factor for HIV-HCV, no. (%)
Previous injection drug use 47 (81.0)
Other 11 (18.9)
Previous C stage (CDC), no. (%) 10 (17.2)
CD4/ml, M (range) 395 (92 – 1500)
,200/ml, no. (%) 3 (5.2)
HIV-RNA copies/mL, M (range) ,50 (,50 – 64200)
.50 copies/mL, no. (%) 13 (22.4)
Antiretroviral treatment, no. (%) 51 (87.9)
2 N(t)RTIs+1 PI 29 (50.0)
2 N(t)RTIs+1 NNRTI 16 (27.6)
Other 6 (10.3)
HCV RNA IU/ml, M (range) 530975 (1054 – 14085574)
.800000 IU/ml, no. (%) 21 (36.2)
Elevated ALT, no. (%) 48 (82.7)
LDL-C mg/dL, M (range) 84 (27 – 181)
Fibrosis stage (biopsy or FibroScan), no. (%) 56 (96.6)
F 0–1 26 (46.4)
F 2 6 (10.3)
F 3 3 (5.2)
F 4 21 (36.2)
IL-28B (rs129679860 SNP), no. (%) 47 (78.3)
CC 25 (43.1)
CT 19 (32.8)
TT 1 (1.7)
M: median. N(t)RTIs: nucleos(t)ide analogue reverse transcriptase inhibitors.
NNRTI: nonnucleoside reverse transcriptase inhibitor. PI: protease inhibitor. LDL-
C: low-density lipoprotein cholesterol.
doi:10.1371/journal.pone.0028115.t001
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Pharmacokinetics results for pegIFN-a-2a and Rbv
A total of 281 samples were available for pegIFN-a-2a and Rbv
determinations throughout the follow-up period, with a median of
6 samples per patient (range, 1 – 9 for pegIFN-a-2a, and 2 -10, for
Rbv). The median Rbv dose was 11.6 mg/kg (range, 7.8 – 19.4).
The results of drug plasma levels are shown in figure 2. Median
intrapatient CV for PegIFN-a-2a and Rbv levels were 24.6%
(range, 0.08 – 0.92) and 40.7% (range, 0.8 – 1.37), and interpatient
variation coefficients were 58.9% and 56.5%, respectively. No
significant differences were found in pegIFN-a-2a concentrations
regarding gender, weight or the presence of cirrhosis.
No relationship was observed between Rbv levels and body weight
(r =20.35; P = 0.8), the administered dose/kg (r = 0.012; P = 0.9) or
the estimated glomerular filtration rate (r =20.88; P = 0.5).
Variables associated with viral responses and relapses
The relationships between baseline patient-related variables
including IL-28B genotype, plasma HCV-RNA, Rbv dose/kg,
PegIFN-a 2a and Rbv levels with RVR, EVR, ETR, SVR and
relapses are shown in table 4. In the multivariable analysis only
HCV-RNA,800000 UI/mL remained independently associated
with RVR (OR: 5.36; CI95: 1.04 – 27.81; P = 0.04), SVR (OR:
Figure 1. Study flow diagram. RVR: rapid virological response. EVR: early virological response. ETR: end of treatment response. SVR: sustained
virological response. AEs: adverse events.
doi:10.1371/journal.pone.0028115.g001
Table 2. Viral responses in HCV/HIV-coinfected patients treated with pegIFN a-2a (135 mg/week) plus ribavirin (800 mg/day).
RVR EVR ETR SVR Relapse
ITT analysis (n = 58), no. (%) 28 (48.3) 50 (86.2) 43 (74.1) 33 (56.9) 10/43 (23.2)
CI95 (%) (35.5–61.1) (77.4–95.0) (62.5–85.7) (43.8–70.0) (10.1–36.4)
#800000 IU/mL (n = 37), no. (%) 23 (62.2) 33 (89.2) 27 (73) 24 (64.9) 3/27 (11.1)
.800000 IU/mL (n = 21), no. (%) 5 (23.8) 17 (81.0) 16 (76.2) 9 (42.9) 7/16 (43.8)
n = 54 n= 53 n= 47 n= 47 n= 43
Per-protocol analysis, no. (%) 28 (51.9) 50 (94.3) 43 (91.4) 33 (70.2) 10 (23.2)
CI95 (%) (38.1–65.6) (87.9–100) (83.2–100) (56.6–83.8) (10.1–36.4)
#800000 IU/mL, no. (%) 23 (67.6) 33 (97.1) 27 (93.1) 24 (82.8) 3 (11.1)
n = 34 n= 34 n= 29 n= 29 n= 27
.800000 IU/mL, no. (%) 5 (25.0) 17 (89.5) 16 (88.9) 9 (50.0) 7 (43.8)
n = 20 n= 19 n= 18 n= 18 n= 16
ITT: intention to treat. RVR: rapid virological response. EVR: early virological response. ETR: end of treatment response. SVR: sustained virological response.
doi:10.1371/journal.pone.0028115.t002
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6.68; CI95: 1.02 – 47.08; P = 0.05), and relapses (OR: 0.14: CI95:
0.021 – 0.99; P = 0.05). Specifically, no relationships were
observed between any virological responses or relapses and
rs129679860 genotype (figure 3), Rbv dose/kg, PegIFN-a-2a or
Rbv levels.
Receiver-operating characteristic curve analysis showed that the
ability of PegIFN-a 2a and Rbv plasma concentrations to identify
viral responders was null. Particularly, the areas under the curve
for RVR, EVR, ETR and SVR for PegIFN-a 2a levels were 0.505
(CI95, 0.315 – 0.697; p = 0.9), 0.811 (CI95, 0.539 – 1; p = 0.07),
0.697 (CI95, 0.338 – 1; p = 0.2), and 0.587 (CI95, 0.372 – 0.801;
p = 0.4), respectively. For Rbv these values were 0.673 (CI95, 0.509
– 0.839; p = 0.4), 0.380 (CI95, 20.028 – 0.784; p = 0.3), 0.375
(CI95, 0.040 – 0.703; p = 0.4), and 0.632 (CI95, 0.043 – 0.817;
p = 0.2), respectively. Nevertheless, the regression model based on
the selected variables explained only moderately the observed
variability in the SVR as Nagelkerke’s R2 was 0.439.
Discussion
This pilot study was aimed to evaluate two hypothesis; first, the
viral efficacy of a pegIFN-a-2a dose lower than the standard of care,
and, second, if a treatment duration of 20 weeks after attaining
undetectable serum HCV-RNA was sufficient in G 3 HCV/HIV-
coinfected patients. Regarding the first hypothesis, the dose-ranging
studies with both formulations of PegIFN-a showed that lower than
the standard doses (90 or 135 mg weekly for pegIFN-a 2a, and
0.75 mg/kg weekly for pegIFN-a 2b) achieved similar SVR rates in
HCV monoinfected patients with G 3, both as a single agent [15–
17] and in combination with Rbv [22–24]. However, to date there
are no data available, to our knowledge, on the use of low doses of
PegIFN-a in HCV/HIV coinfected patients.
Our results suggest that pegIFN-a-2a given at 135 mg once
weekly might be as effective as the standard 180 mg dose, when
administered together with 800 mg daily of Rbv in G3 HCV/
HIV-coinfected patients, since both on treatment RVR and EVR
rates in our study (51.9%, and 94.3%, respectively) were similar to
those observed in other studies as the Apricot trial (37%, and 88%,
respectively) [21], and our previous study (RVR, 58.3%; EVR,
97.5%) in which similar patients were treated with weekly 180 mg
pegIFN-a 2a [14]. These results are despite the use of a stricter
criterion for a negative HCV viremia in the current study
(#15 UI/mL by quantitative PCR assay vs.,50 UI/mL by
qualitative PCR). In fact, five patients in our study had viremia
levels between 18 and 48 IU/mL at week 4, which would have
rated them as rapid responders by qualitative methods. Unfortu-
nately, there are no other studies on pegIFN-a 2a plus Rbv
(800 mg/day) in HIV-coinfected patients with CHC G3 which
reported EVR rates on treatment for comparison. In the Presco
study a SVR rate of 79.3% was observed after standard pegIFN-a-
2a 180 mg dose plus higher Rbv dose (1000–1200 mg/day) instead
a flat dose of 800 mg/day [25].
Table 3. Adverse events or intercurrent illness throughout treatment with weekly pegIFN-a-2a (135 mg) plus oral Ribavirin
(400 mg twice daily); n = 58 patients.
Total Grade 1 -2 Grade 3 Grade 4
no. (%) no. (%) no. (%) no. (%)
Flu-like syndrome 30 (51.7) 27 (46.5) 3 (5.1)
Myalgia 9 (15.5) 8 (13.7) 1 (1.7)
Fatigue 28 (48.2) 28 (48.2)
Unintentional weight loss $10% 14 (24.1) 14 (24.1)
Anorexia 23 (39.6) 23 (39.6)
Depression 14 (24.1) 13 (22.4) 1 (1.7)
Irritability - nervousness 12 (20.6) 11 (18.9) 1 (1.7)
Insomnia 11 (18.9) 10 (16.7) 1 (1.7)
Nausea – vomiting 15 (25.8) 15 (25.8)
Anemia 7 (12.0) 6 (10.3) 1 (1.7)
Neutropenia 21 (36.2) 18 (31.0) 3 (5.1)
Thrombocytopenia 10 (18.3) 10 (18.3)
Other
- Subarachnoid hemorrhage (death) 1 (1.7) 1 (1.7)
- Neuroleptic malignant syndrome (death) 1 (1.7) 1 (1.7)
- Sudden death 1 (1.7) 1 (1.7)
- Pneumococcal pneumonia 1 (1.7) 1 (1.7)
- Esophageal stenosis (relapse) 1 (1.7) 1 (1.7)
- Thrush 1 (1.7) 1 (1.7)
- Deep vein thrombosis 1 (1.7) 1 (1.7)
- Cough 2 (3.4) 2 (3.4)
- Headache 2 (3.4) 2 (3.4)
- Dizziness 1 (1.7) 1 (1.7)
- Injection site erythema 1 (1.7) 1 (1.7)
doi:10.1371/journal.pone.0028115.t003
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Figure 2. Peginterferon-a-2a (A) and ribavirin (B) trough plasma levels at different time points. Median (range).
doi:10.1371/journal.pone.0028115.g002
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Our hypothesis is also supported by the lack of relationship
between pegIFN-a 2a plasma levels and the rate of viral response,
despite those being lower than that observed previously with
pegIFN-a 2a at 180 mg once weekly (2467; range, 757 – 5136 vs.
4762 pg/mL; range, 1419 – 6451) [14]. However, while a
treatment duration of 20 weeks after attaining undetectable serum
HCV-RNA seems adequate in patients achieving RVR regardless
of their baseline HCV-RNA (in fact, both relapsing patients had
baseline viremias,5000 UI/mL), the high relapse rate in patients
with no RVR suggests that extending treatment to only 20 weeks
after achieving negativization of viremia is not sufficient and thus a
longer treatment period is needed.
No relationship was observed between Rbv plasma levels and
viral responses during therapy or SVR rate, similar to results in
our previous study [14]. Moreover, we did not find any
relationship between the administered dose per kg of Rbv and
its plasma levels achieved at just 12 hours after drug intake.
Therefore, we believe the current recommendation of dosing Rbv
in mg/kg according to the patient’s weight is still a matter of
debate, particularly in G2/3 in which doses of 400 and 800 mg/
day might produce equivalent SVR rates in patients infected with
HCV G3 [26].
Likewise, we observed no relationship between rs129679860
IL28B genetic polymorphisms and virological responses to
pegIFN-a 2a plus Rbv in our patients with CHC G3, as has
been previously reported in both G3 monoinfected and HCV/
HIV-coinfected patients [27–29], although the existing data on
this issue are not entirely homogeneous [30].
Regarding the incidence of toxicity, it is remarkable that both
clinical and laboratory AEs were just mild and did not motivate
Figure 3. Percentage of virological responses and relapses as function of rs129679860 genotype (CC vs. CT/TT). RVR: rapid virological
response; EVR: early virological response; ETR: end of treatment response; SVR: sustained virological response.
doi:10.1371/journal.pone.0028115.g003
Table 4. Factors predictive of rapid (RVR) and sustained virological response (SVR) to anti-hepatitis C virus therapy.
Univariate nonparametric analysis Multivariable analysis
RVR SVR
Factor RVR (%) P SVR (%) P Adjusted OR (CI95) P Adjusted OR (CI95) P
Plasma HCV RNA
(#vs. 800000 IU/mL) 67.6 vs. 25.0 0.003 82.8 vs. 50.0 0.02 5.36 (1.04 – 27.81) 0.04 6.68 (1.01 – 47.08) 0.05
LDL-C mg/dL
($80 vs.,80) 70.0 vs. 33.3 0.02 88.9 vs. 47.4 0.008 3.08 (0.67 – 14.05) 0.14 3.31 (0.45 – 24.33) 0.23
Cirrhosis
(no vs. yes) 60.6 vs. 40.0 0.12 74.2 vs. 62.5 0.30 2.51 (0.51 – 12.23) 0.25
Use of TDF vs. ABV 54.5 vs. 60.0 0.49 72.4 vs. 87.5 0.35 n.a. n.a.
IL28B
(CC vs. CT/TT) 43.5 vs. 42.1 0.26 63.2 vs. 68.4 0.50 n.a. n.a.
Treatment exposition
($80% vs.,80%) n.a. 81.6 vs. 40.0 0.07 n.a. 7.81 (0.37 – 161.4) 0.18
TDF: tenofovir. ABV: abacavir. n.a.: not applicable.
doi:10.1371/journal.pone.0028115.t004
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dose reductions in patients receiving the 135 mg dose. Four out of
the 8 cases of AEs which motivated treatment interruption were
considered unrelated to study treatment. Thus, the rate of drop-
outs due to treatment-related toxicity was only 6.9%, which
compare favorably with previous studies in which the rate of
serious AEs varied between 10 and 18% [4,5,9,11]. Moreover,
these drop-outs were mainly caused by poor tolerance rather than
by the severity of the AEs.
The main limitation of our study is the fact that it is a single-arm
trial in which the results were compared with those observed in
earlier clinical trials. However, we believe such a study had to be
carried out prior to the design of a randomized controlled trial
allowing for a one-to-one comparison between efficacy and safety
of weekly 135 and 180 mg doses of pegIFN-a-2a in G3 HCV/
HIV-coinfected patients. Furthermore, a high drop-out rate
(18.9%), mainly due to low grade AEs and those unrelated to
the study medication, penalized the intention-to-treat analysis
results.
In conclusion, our results suggest that weekly 135 mg pegIFN-a
2a could be as effective as the standard 180 mg dose, with lower
incidence of severe AEs, supporting the design of a randomized
controlled trial allowing for a one-to-one comparison between
efficacy and safety of weekly 135 and 180 mg doses of pegIFN-a-2a
in G3 HCV/HIV-coinfected patients. Our data evidence that
neither the rs129679860 IL-28B genetic polymorphisms nor
plasma pegIFN-a-2a or Rbv levels influence the virological
responses in G3 HCV/HIV-coinfected patients. On the other
hand, while a 24-week treatment duration appears to be
appropriate in patients achieving negative viremia on week 4,
extending treatment duration up to just 20 weeks beyond
negativization of viremia is associated with a high relapse rate in
those patients not achieving RVR, and therefore a more
prolonged treatment is warranted in these patients.
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